{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:31:56Z","timestamp":1792074716648,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.smim.2011.08.015","type":"journal-article","created":{"date-parts":[[2011,9,21]],"date-time":"2011-09-21T23:50:59Z","timestamp":1316649059000},"page":"136-142","source":"Crossref","is-referenced-by-count":28,"title":["Treatment options and strategies for antibody mediated rejection after renal transplantation"],"prefix":"10.1016","volume":"24","author":[{"given":"Matthew H.","family":"Levine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Abt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2011.08.015_bib0005","unstructured":"United States Organ Procurement and Transplantation Network (OPTN) Database. US Department of Health and Human Services, Health Resources and Services Administration; May 11, 2011."},{"issue":"10","key":"10.1016\/j.smim.2011.08.015_bib0010","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00467-009-1386-4","article-title":"Advances in diagnosing and managing antibody-mediated rejection","volume":"25","author":"Jordan","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0015","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1111\/j.1399-0012.2010.01306.x","article-title":"The effect of HLA mismatch on highly sensitized renal allograft recipients","volume":"24","author":"Paramesh","year":"2010","journal-title":"Clin Transplant"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1399-3046.2004.00214.x","article-title":"Transplanting patients with a positive donor-specific crossmatch: a single center's perspective","volume":"8","author":"Montgomery","year":"2004","journal-title":"Pediatr Transplant"},{"issue":"3","key":"10.1016\/j.smim.2011.08.015_bib0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.smim.2011.08.015_bib0030","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1034\/j.1600-6143.2003.00180.x","article-title":"Overcoming a positive crossmatch in living-donor kidney transplantation","volume":"3","author":"Gloor","year":"2003","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.smim.2011.08.015_bib0035","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.smim.2011.08.015_bib0040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2215\/CJN.01651105","article-title":"Presensitization: the problem and its management","volume":"1","author":"Jordan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.smim.2011.08.015_bib0045","first-page":"199","article-title":"Renal transplantation at the Johns Hopkins Comprehensive Transplant Center","author":"Montgomery","year":"2003","journal-title":"Clin Transpl"},{"issue":"1","key":"10.1016\/j.smim.2011.08.015_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-2277.2004.tb00376.x","article-title":"Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies","volume":"17","author":"Glotz","year":"2004","journal-title":"Transpl Int"},{"issue":"10","key":"10.1016\/j.smim.2011.08.015_bib0055","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/00007890-200011270-00023","article-title":"A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants","volume":"70","author":"Schweitzer","year":"2000","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.smim.2011.08.015_bib0060","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/TP.0b013e31819f2024","article-title":"ABO incompatible renal transplantation: a paradigm ready for broad implementation","volume":"87","author":"Montgomery","year":"2009","journal-title":"Transplantation"},{"issue":"7465","key":"10.1016\/j.smim.2011.08.015_bib0065","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(66)92829-7","article-title":"Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells","volume":"2","author":"Kissmeyer-Nielsen","year":"1966","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.smim.2011.08.015_bib0070","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJM196809192791201","article-title":"Hyperacute renal-homograft rejection in man","volume":"279","author":"Williams","year":"1968","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.smim.2011.08.015_bib0075","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1600-6143.2006.01416.x","article-title":"Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation","volume":"6","author":"Gloor","year":"2006","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1399-0012.2009.01036.x","article-title":"Differential outcomes in 3 types of acute antibody-mediated rejection","volume":"23","author":"Rafiq","year":"2009","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.smim.2011.08.015_bib0085","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656566.2011.525219","article-title":"Antibody-mediated rejection in kidney transplantation: an update","volume":"12","author":"Lucas","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00041552-200211000-00007","article-title":"Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment","volume":"11","author":"Mauiyyedi","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/01.TP.0000129256.84027.D6","article-title":"Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols","volume":"78","author":"Montgomery","year":"2004","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0100","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1034\/j.1600-6143.2003.00072.x","article-title":"Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection","volume":"3","author":"Racusen","year":"2003","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.smim.2011.08.015_bib0105","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1681\/ASN.V1341091","article-title":"Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury","volume":"13","author":"Bohmig","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0110","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/TP.0b013e3181e36e08","article-title":"Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation","volume":"90","author":"Riethmuller","year":"2010","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.smim.2011.08.015_bib0115","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0120","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1600-6143.2007.02072.x","article-title":"Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation","volume":"8","author":"Lefaucheur","year":"2008","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.smim.2011.08.015_bib0125","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00007890-200210270-00025","article-title":"All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies","volume":"74","author":"Lee","year":"2002","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.smim.2011.08.015_bib0130","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.TP.0000055833.65192.3B","article-title":"Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome","volume":"75","author":"Worthington","year":"2003","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.smim.2011.08.015_bib0135","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1600-6143.2004.00360.x","article-title":"Predicting kidney graft failure by HLA antibodies: a prospective trial","volume":"4","author":"Terasaki","year":"2004","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.smim.2011.08.015_bib0140","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","article-title":"Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure","volume":"9","author":"Einecke","year":"2009","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.smim.2011.08.015_bib0145","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.TP.0000122187.76518.BC","article-title":"Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin","volume":"77","author":"Shah","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.smim.2011.08.015_bib0150","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00007890-199402270-00014","article-title":"Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ","volume":"57","author":"Tyan","year":"1994","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0155","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00007890-199308000-00015","article-title":"Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients","volume":"56","author":"Glotz","year":"1993","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.smim.2011.08.015_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/TP.0b013e3181a9e89a","article-title":"Intravenous immunoglobulin a natural regulator of immunity and inflammation","volume":"88","author":"Jordan","year":"2009","journal-title":"Transplantation"},{"issue":"35","key":"10.1016\/j.smim.2011.08.015_bib0165","doi-asserted-by":"crossref","first-page":"14104","DOI":"10.1073\/pnas.0700506104","article-title":"Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death","volume":"104","author":"Arumugam","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.smim.2011.08.015_bib0170","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)\u20322-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins","volume":"9","author":"Basta","year":"2003","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0175","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.smim.2011.08.015_bib0180","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/01.tp.0000226073.20185.b1","article-title":"Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors","volume":"81","author":"Tha-In","year":"2006","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1034\/j.1600-6143.2003.00011.x","article-title":"Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells","volume":"3","author":"Toyoda","year":"2003","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0190","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00007890-199809270-00017","article-title":"Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action","volume":"66","author":"Jordan","year":"1998","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.smim.2011.08.015_bib0195","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/01.TP.0000080685.31697.FC","article-title":"Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients","volume":"76","author":"Jordan","year":"2003","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.smim.2011.08.015_bib0200","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination Plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0205","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00007890-200009270-00006","article-title":"Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients","volume":"70","author":"Montgomery","year":"2000","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.smim.2011.08.015_bib0210","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S0041-1345(02)03044-0","article-title":"Preemptive therapy with plasmapheresis\/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match","volume":"34","author":"Sonnenday","year":"2002","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0215","first-page":"83","article-title":"Pulmonary and renal toxicity of intravenous immunoglobulin","volume":"36","author":"Rault","year":"1991","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0220","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1034\/j.1600-6143.2003.00121.x","article-title":"Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications","volume":"3","author":"Jordan","year":"2003","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.smim.2011.08.015_bib0225","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.TP.0000060252.57111.AC","article-title":"Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection","volume":"75","author":"Rocha","year":"2003","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.smim.2011.08.015_bib0230","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1098-1101(2000)15:3<180::AID-JCA5>3.0.CO;2-6","article-title":"Treatment of antibody-mediated accelerated rejection using plasmapheresis","volume":"15","author":"Madan","year":"2000","journal-title":"J Clin Apher"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0235","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1526-0968.2003.00101.x","article-title":"Plasmapheresis in C4d-positive acute humoral rejection following kidney transplantation: a review of 4 cases","volume":"7","author":"Lennertz","year":"2003","journal-title":"Ther Apher Dial"},{"issue":"1\u20133","key":"10.1016\/j.smim.2011.08.015_bib0240","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12026-009-8157-y","article-title":"Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange","volume":"47","author":"Warren","year":"2010","journal-title":"Immunol Res"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0245","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-6143.2005.01178.x","article-title":"A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody","volume":"6","author":"Stegall","year":"2006","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.smim.2011.08.015_bib0250","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jca.20247","article-title":"Introduction and overview of therapeutic apheresis","volume":"25","author":"Okafor","year":"2010","journal-title":"J Clin Apher"},{"issue":"25","key":"10.1016\/j.smim.2011.08.015_bib0255","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0260","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"Suppl. 12","key":"10.1016\/j.smim.2011.08.015_bib0265","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/01.tp.0000296122.19026.0f","article-title":"Pharmacodynamics of rituximab in kidney transplantation","volume":"84","author":"Genberg","year":"2007","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.smim.2011.08.015_bib0270","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0275","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-6143.2006.01632.x","article-title":"The effect of desensitization protocols on human splenic B-cell populations in vivo","volume":"7","author":"Ramos","year":"2007","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.smim.2011.08.015_bib0280","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.smim.2011.08.015_bib0285","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0290","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1600-6143.2004.00454.x","article-title":"Rituximab as treatment for refractory kidney transplant rejection","volume":"4","author":"Becker","year":"2004","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.smim.2011.08.015_bib0295","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/j.1600-6143.2008.02411.x","article-title":"A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation","volume":"8","author":"Zarkhin","year":"2008","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.smim.2011.08.015_bib0300","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/01.tp.0000282786.58754.2b","article-title":"Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection","volume":"84","author":"Steinmetz","year":"2007","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.smim.2011.08.015_bib0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-0012.2008.00902.x","article-title":"Impact of rituximab therapy for treatment of acute humoral rejection","volume":"23","author":"Kaposztas","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.smim.2011.08.015_bib0310","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1042\/0264-6021:3460155","article-title":"Subcellular localization of proteasomes and their regulatory complexes in mammalian cells","volume":"346","author":"Brooks","year":"2000","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.smim.2011.08.015_bib0315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","article-title":"The ubiquitin-proteasome proteolytic pathway","volume":"79","author":"Ciechanover","year":"1994","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.smim.2011.08.015_bib0320","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0092-8674(94)90462-6","article-title":"Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules","volume":"78","author":"Rock","year":"1994","journal-title":"Cell"},{"issue":"5224","key":"10.1016\/j.smim.2011.08.015_bib0325","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7624798","article-title":"Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27","volume":"269","author":"Pagano","year":"1995","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.smim.2011.08.015_bib0330","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.smim.2011.08.015_bib0335","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.smim.2011.08.015_bib0340","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.smim.2011.08.015_bib0345","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ctrv.2005.10.001","article-title":"Bortezomib a novel proteasome inhibitor, in the treatment of hematologic malignancies","volume":"31","author":"Jackson","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.smim.2011.08.015_bib0350","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.smim.2011.08.015_bib0355","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.smim.2011.08.015_bib0360","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":"Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.smim.2011.08.015_bib0365","first-page":"377","article-title":"The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib","author":"Lonze","year":"2009","journal-title":"Clin Transpl"},{"key":"10.1016\/j.smim.2011.08.015_bib0370","first-page":"461","article-title":"Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report","author":"Manitpisitkul","year":"2009","journal-title":"Clin Transpl"},{"issue":"1","key":"10.1016\/j.smim.2011.08.015_bib0375","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production","volume":"9","author":"Perry","year":"2009","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.smim.2011.08.015_bib0380","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/TP.0b013e3181d9e1c0","article-title":"Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates","volume":"89","author":"Wahrmann","year":"2010","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.smim.2011.08.015_bib0385","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1600-6143.2009.02968.x","article-title":"Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies","volume":"10","author":"Sberro-Soussan","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.smim.2011.08.015_bib0390","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1600-6143.2010.03025.x","article-title":"What should work, may not","volume":"10","author":"Kirk","year":"2010","journal-title":"Am J Transplant"},{"issue":"Suppl. 2 (s2)","key":"10.1016\/j.smim.2011.08.015_bib0395","first-page":"241","article-title":"Prevention of acute humoral rejection with C5 inhibition","volume":"9","author":"Stegall","year":"2009","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.smim.2011.08.015_bib0400","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1111\/j.1600-6143.2010.03191.x","article-title":"Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access","volume":"10","author":"Lonze","year":"2010","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.smim.2011.08.015_bib0405","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.smim.2011.08.015_bib0410","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.smim.2007.12.002","article-title":"Plasma cell development: from B-cell subsets to long-term survival niches","volume":"20","author":"Fairfax","year":"2008","journal-title":"Semin Immunol"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0415","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.4049\/jimmunol.1001155","article-title":"Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics","volume":"185","author":"Good-Jacobson","year":"2010","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.smim.2011.08.015_bib0420","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.4049\/jimmunol.169.8.4213","article-title":"The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity","volume":"169","author":"Minges Wols","year":"2002","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0425","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ni.1981","article-title":"Eosinophils are required for the maintenance of plasma cells in the bone marrow","volume":"12","author":"Chu","year":"2011","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.smim.2011.08.015_bib0430","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","article-title":"Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL","volume":"180","author":"Benson","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.smim.2011.08.015_bib0435","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.4049\/jimmunol.171.4.1684","article-title":"Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals","volume":"171","author":"Cassese","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.smim.2011.08.015_bib0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-065X.2003.00041.x","article-title":"Homing of antibody secreting cells","volume":"194","author":"Cyster","year":"2003","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.smim.2011.08.015_bib0445","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1084\/jem.194.1.45","article-title":"A coordinated change in chemokine responsiveness guides plasma cell movements","volume":"194","author":"Hargreaves","year":"2001","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.smim.2011.08.015_bib0450","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.4049\/jimmunol.169.3.1277","article-title":"Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response","volume":"169","author":"Hauser","year":"2002","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.smim.2011.08.015_bib0455","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF02983377","article-title":"Survival and proliferation factors of normal and malignant plasma cells","volume":"78","author":"Klein","year":"2003","journal-title":"Int J Hematol"},{"issue":"Suppl. 132.5","key":"10.1016\/j.smim.2011.08.015_bib0460","article-title":"RANK-L expression marks long-lived plasma cells","volume":"184","author":"Quinn","year":"2010","journal-title":"J Immunol"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532311000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532311000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T01:28:48Z","timestamp":1638754128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532311000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1044532311000911"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2011.08.015","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}